A reduction in proteinuria and albuminuria has long been proposed as a surrogate biomarker for clinically validated end points for interventional trials in patients with kidney disease. Taken together, the findings of two recent landmark meta-analyses present a formidable argument favouring such surrogacy but some uncertainty remains.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Cravedi, P. & Remuzzi, G. Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease Br. J. Clin. Pharmacol. 76, 516–523 (2013).
Eijkelkamp, W. B. et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J. Am. Soc. Nephrol. 18, 1540–1546 (2007).
Glassock, R. J. Control of albuminuria in overt diabetic nephropathy: durability counts. Nephrol. Dial. Transplant. 31, 1371–1373 (2016).
Fried, L. F. & Lewis, J. Albuminuria is not an appropriate therapeutic target in patients with CKD: the con view. Clin. J. Am. Soc. Nephrol. 10, 1089–1093 (2015).
Lambers Heerspink, H. J. & Gansevoort, R. T. Albuminuria is an appropriate therapeutic target in patients with CKD: the pro view. Clin. J. Am. Soc. Nephrol. 10, 1079–1088 (2015).
Coresh, J. et al. Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes Endocrinol. 7, 115–127 (2019).
Heerspink, H. J. L. et al. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol. 7, 128–139 (2019).
Inker, L. A. et al. Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis. Am. J. Kidney Dis. 64, 74–85 (2014).
Thompson, A. et al. Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin. J. Am. Soc. Nephrol. https://doi.org/10.2215/CJN.08600718 (2019).
Cattran, D. C. et al. The impact of sex in primary glomerulonephritis. Nephrol. Dial. Transplant. 23, 2247–2253 (2008).
Acknowledgements
The author thanks F. Fervenza (Mayo Clinic, USA) for review of a draft version of this manuscript before submission.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
R.J.G is a consultant for Bristol-Myers Squibb, Chemocentryx, Apellis, Ionis, Achillion, Omeros and Mallinckrodt. He owns stock in Reata, Inc. (bardoxolone) and receives editorial stipends from Wolters-Kluwer (UpToDate) and Karger Publications (American Journal of Nephrology and Nephrology Viewpoints).
Rights and permissions
About this article
Cite this article
Glassock, R.J. Albuminuria: a target for clinical trials in kidney disease?. Nat Rev Nephrol 15, 257–258 (2019). https://doi.org/10.1038/s41581-019-0123-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41581-019-0123-x
This article is cited by
-
Therapeutic trials in adult FSGS: lessons learned and the road forward
Nature Reviews Nephrology (2021)